Z hypnotics in the management of narcolepsy: a case series.

IF 3.5 3区医学 Q1 CLINICAL NEUROLOGY Journal of Clinical Sleep Medicine Pub Date : 2024-12-30 DOI:10.5664/jcsm.11546

Amer Aboukasm, Anthony N Reffi, Christopher L Drake

{"title":"Z hypnotics in the management of narcolepsy: a case series.","authors":"Amer Aboukasm, Anthony N Reffi, Christopher L Drake","doi":"10.5664/jcsm.11546","DOIUrl":null,"url":null,"abstract":"Study objectives: Here we report our experience treating patients with narcolepsy using benzodiazepine receptor agonists (BzRA), zolpidem (Zol) or eszopiclone (Esz) taken at bedtime for both excessive daytime sleepiness (EDS) and cataplexy.Methods: We reviewed the medical records of 53 patients diagnosed with narcolepsy, between 2002 and 2023. Twenty-three patients, 8 with type1 (NT1), 13 with type 2 (NT2) and 2 with secondary narcolepsy, were treated with BzRA's (20 Zol and 3 Esz).Results: Seven out of 8 (88%) with NT1, 9 out of 13 (69%) with NT2 and 2 out of 2 (100%) with secondary narcolepsy, treated with BzRA, had good to excellent subjective response in their symptoms of EDS and/or cataplexy; 5 patients, 1 of whom with NT1, had marginal or no response. Three of the responding patients remained on zolpidem in monotherapy (ie. no stimulants).Conclusions: The BzRa drugs may be effective to manage several of the cardinal symptoms of narcolepsy, regardless of the narcolepsy type. Placebo controlled trials are needed to confirm our observations.","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Sleep Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5664/jcsm.11546","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Study objectives: Here we report our experience treating patients with narcolepsy using benzodiazepine receptor agonists (BzRA), zolpidem (Zol) or eszopiclone (Esz) taken at bedtime for both excessive daytime sleepiness (EDS) and cataplexy.

Methods: We reviewed the medical records of 53 patients diagnosed with narcolepsy, between 2002 and 2023. Twenty-three patients, 8 with type1 (NT1), 13 with type 2 (NT2) and 2 with secondary narcolepsy, were treated with BzRA's (20 Zol and 3 Esz).

Results: Seven out of 8 (88%) with NT1, 9 out of 13 (69%) with NT2 and 2 out of 2 (100%) with secondary narcolepsy, treated with BzRA, had good to excellent subjective response in their symptoms of EDS and/or cataplexy; 5 patients, 1 of whom with NT1, had marginal or no response. Three of the responding patients remained on zolpidem in monotherapy (ie. no stimulants).

Conclusions: The BzRa drugs may be effective to manage several of the cardinal symptoms of narcolepsy, regardless of the narcolepsy type. Placebo controlled trials are needed to confirm our observations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Z催眠在治疗发作性睡病中的应用：一个病例系列。

研究目的：在这里，我们报告了我们使用苯二氮卓受体激动剂（BzRA）、唑吡坦（Zol）或艾索匹克隆（Esz）治疗嗜睡症患者的经验，这些患者在睡前服用唑吡坦（Zol）来治疗白天过度嗜睡（EDS）和猝倒。方法：回顾性分析2002 ~ 2023年间53例发作性睡病患者的病历资料。23例患者接受BzRA治疗，其中8例为1型（NT1）， 13例为2型（NT2）， 2例为继发性发作性睡病（20 Zol, 3 Esz）。结果：接受BzRA治疗的8例NT1患者中有7例（88%），13例NT2患者中有9例（69%），2例继发性发作性睡病患者中有2例（100%），其EDS和/或猝倒症状的主观反应良好至优异；5例患者（其中1例为NT1）边际或无反应。其中3名有反应的患者继续使用唑吡坦单药治疗。没有兴奋剂)。结论：与发作性睡病类型无关，BzRa类药物可有效治疗发作性睡病的几种主要症状。需要安慰剂对照试验来证实我们的观察结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Clinical Sleep Medicine CLINICAL NEUROLOGY-

CiteScore

6.20

自引率

7.00%

发文量

321

审稿时长

1 months

期刊介绍： Journal of Clinical Sleep Medicine focuses on clinical sleep medicine. Its emphasis is publication of papers with direct applicability and/or relevance to the clinical practice of sleep medicine. This includes clinical trials, clinical reviews, clinical commentary and debate, medical economic/practice perspectives, case series and novel/interesting case reports. In addition, the journal will publish proceedings from conferences, workshops and symposia sponsored by the American Academy of Sleep Medicine or other organizations related to improving the practice of sleep medicine.